Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study

McCloskey, E.V. orcid.org/0000-0003-0177-8140, Johansson, H., Harvey, N.C. et al. (3 more authors) (2021) Romosozumab efficacy on fracture outcomes is greater in patients at high baseline fracture risk: a post hoc analysis of the first year of the frame study. Osteoporosis International. ISSN 0937-941X

Abstract

Metadata

Authors/Creators:
Copyright, Publisher and Additional Information: © The Author(s) 2021. Open Access: This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.
Keywords: Fracture reduction; Fracture risk; FRAX; Romosozumab
Dates:
  • Accepted: 30 December 2020
  • Published (online): 3 February 2021
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Sheffield Teaching Hospitals
Depositing User: Symplectic Sheffield
Date Deposited: 09 Mar 2021 12:40
Last Modified: 09 Mar 2021 12:40
Status: Published online
Publisher: Springer Science and Business Media LLC
Refereed: Yes
Identification Number: https://doi.org/10.1007/s00198-020-05815-0
Related URLs:

Share / Export

Statistics